APIIC Hosts Plenary Event: Pathway to Build Supply Chain Resilience for Critical Drugs

The API Innovation Center Receives $9.45 Million ‘Advanced Manufacturing Resiliency Grant’ from Missouri Technology Corporation

Strengthening Missouri’s Position as a National Leader in Active Pharmaceutical Ingredient (API) Reshoring, Sparking Job Growth and Economic Development Throughout the State

Learn About the Grant

The APIIC is Strengthening Domestic Production of Active Pharmaceutical Ingredients (API) Through Advanced Manufacturing

Our nation’s over-reliance on foreign-sourced API has created both a public health and national security risk. The APIIC is de-risking the return of API production to the U.S.

What we do

Continuous Flow Manufacturing

The continuous flow manufacturing process can significantly improve drug quality, address shortages of essential medicines, accelerate time to market, and strengthen the overall manufacturing competitiveness of the U.S.

Learn the Benefits

WHO WE ARE

Driving Innovation, Delivering U.S.-Manufactured APIs

The API Innovation Center (APIIC) is a non-profit organization dedicated to enabling the delivery of market-competitive commercial supply of U.S.-made Active Pharmaceutical Ingredients (APIs) to address critical needs in the healthcare supply chain while fostering job growth throughout the St. Louis region.

ABOUT API innovation Center

The APIIC is a membership-based organization comprised of a network of companies, academic and research institutions, experts and startups spanning the API advanced manufacturing supply chain.

Join the center

The Lomustine Project

Solving the Lomustine API Crisis for Glioblastoma Patients

The APIIC’s initial project is the U.S. production of lomustine, a chemotherapy drug used to treat glioblastoma, the most common and aggressive form of brain cancer. There is currently no U.S. source of lomustine. According to the Society for Neuro-Oncology, “the field of neuro-oncology is in the midst of a crisis with lomustine.” The APIIC is working in partnership with Continuity Pharma and the Glioblastoma Foundation to resolve the lomustine crisis utilizing the advanced technologies of continuous flow manufacturing.

Our Projects